Cancer patients who are uninsured or are on Medicaid benefit less from experimental treatments.<br />According to UPI, this is true even if they get into clinical trials.<br />New research reveals Medicaid beneficiaries and the uninsured are only 23% more likely to achieve added survival from an experimental treatment.<br />People with private health insurance, however, are 66% more likely to derive added survival from interventions still under investigation.<br />The findings suggest that the uninsured and those on Medicaid effectively might be excluded from clinical trials because the costs aren't reimbursed.<br />Therefore, Columbia University researchers say patients don't have access to the potentially beneficial approaches being investigated.
